No Data
No Data
A new generation of anti-insomnia drugs is coming. Simcere Pharma (02096) takes the lead in the billion-dollar market.
The launch of the new drug by Dalier Rayon has been accepted by NMPA. Simcere Pharma has added a heavyweight product in the central nervous field, further consolidating the company's dominant position in the central nervous field and forming a bullish development for Simcere Pharma.
Simcere Pharma (02096) spent 5.1784 million Hong Kong dollars to repurchase 0.935 million shares on July 19th.
Simcere Pharma (02096) announced that on July 19, 2024, it spent 5.1784 million Hong Kong dollars...
China Securities Co.,Ltd: Accelerating development of the self-immunity market to promote the improvement and efficiency of the domestic innovative drug industry.
The patient population with autoimmune diseases and type II inflammation is growing rapidly, the market size is second only to cancer drugs, but still in a period of accelerated development. Existing drugs still have huge room for improvement in efficacy and safety.
Simcere Pharmaceutical Group's Insomnia Drug's NDA Accepted by NMPA
Simcere Pharma (02096.HK): Kewei Ke (Dali Reishen hydrochloride tablets) new drug application (NDA) has been accepted by the State Drug Administration.
On July 16th, Gelunhui announced that Simcere Pharma (02096.HK) and Idorsia Pharmaceuticals Ltd. (Idorsia) had their new insomnia drug, Kewei Ke (DARILEZ tablets (darilerele hydrochloride)), which is a dual orexin receptor antagonist (DORA), blocking the arousal-promoting peptide neurotransmitters (orexin A and orexin B) and their receptors, accepted by the National Medical Products Administration (NMPA) for a new drug application (NDA) in China. It does not act like a sedative.
Express News | Simcere Pharmaceutical - New Drug Application of Quviviq Accepted by Nmpa
No Data